1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
APT Medical Inc.

APT Medical Inc.

688617.SS
APT Medical Inc.CN flagShanghai Stock Exchange
201.48
CNY
-7.21
- -
28.42BMarket Cap
APT Medical Inc.
688617.SS
(Shanghai Stock Exchange)

Recent

price

201.48

P/E

ratio

- -

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
1.46
2.3
3.84
4.57
6.05
8.69
11.81
14.73
18.33
16.17
Revenue per Share
0.33
0.2
0.78
1.06
1.52
2.56
3.82
4.8
5.82
5.36
Basic EPS, GAAP
-0.12
-0.13
-0.12
0.99
0.1
1.6
3.49
0.66
4.84
-2.42
Free Cash Flow per Basic Share
- -
- -
0.06
0.01
0.24
0.49
0.8
0.96
1.21
2.16
Dividend per Share
1.23
1.43
1.8
2.75
3.44
5.38
8.41
12.36
17.24
14.44
Book Value per Share
2.03
2.56
2.3
3.98
12.83
12.52
13.1
15.01
19.09
16.93
Tangible Book Value per Share
105
105
105
105
137
140
140
140
141
141
Basic Weighted Avg Shares
153
242
404
479
829
1,216
1,650
2,066
2,584
2,279
Sales/Revenue/Turnover
10.3
9.37
23.43
25.07
24.12
31.97
34.99
36.55
36.56
37.28
Operating Margin (%)
8
9
15
20
33
48
65
87
111
- -
Depreciation Expense
34
22
83
111
208
358
534
673
821
756
Net Income, GAAP
12.62
28.16
14.54
14.04
12.05
13.91
12.45
11.77
13.73
11.71
Effective Tax Rate (%)
22.51
8.9
20.44
23.11
25.09
29.44
32.35
32.59
31.76
33.17
Profit Margin (%)
126
159
173
237
1,359
1,146
1,168
1,211
1,663
1,433
Working Capital
- -
- -
104
28
17
9
9
5
12
10
LT Debt
214
271
346
450
1,791
1,791
1,962
2,555
3,130
2,829
Total Equity
- -
6.52
21.12
20.93
14.96
18.05
25.69
28.54
28.22
29.31
Return on Invested Capital (%)
- -
18.12
35.91
36.34
51.88
55.27
51.01
44.47
39.05
43.8
Return on Capital (%)
- -
15.35
48.48
46.29
54.65
58.47
55.4
46.29
39.41
44.21
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
6
7
6
LT Borrowings
- -
- -
4
LT Finance Leases
5
7
6
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
141
141
141
Market Capitalization
35,986
37,631
41,843

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
1,617
1,751
1,782
Cash, Cash Equivalents & STI
1,081
1,198
1,206
Accounts Receivable, Net
83
90
88
Inventories
399
419
441
Total Current Liabilities
406
371
348
Payables & Accruals
- -
- -
- -
ST Debt
6
7
6
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
22.53%
Free Cash Flow
- -
416.54%
632.37%
Net Income, GAAP
- -
51.4%
21.91%
Sales/Revenue/Turnover
- -
41.11%
25.08%
Total Cash Common Dividend
- -
493.22%
27.1%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
455
546
524
541
2,066
2025
564
650
716
- -
2,584
2026
704
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1
- -
- -
- -
4.8
2025
1.3
- -
- -
- -
5.82
2026
1.64
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.96
2025
- -
- -
- -
- -
1.21
2026
- -
- -
- -
- -
- -
Similar Companies
Zhejiang Orient Gene Biotech Co., Ltd. (688298.SS)
3-D Matrix, Ltd. (DMTRF)
LivaNova PLC (LIVN)
Carmat S.A. (ALCAR.PA)
Paragon 28, Inc. (FNA)
Analytica Limited (ALT.AX)
Business
APT Medical Inc. (688617.SS) develops, manufactures and markets electrophysiology and vascular interventional medical devices for cardiovascular procedures in China and internationally. The company provides electrophysiological products including mapping catheters, ablation catheters, transseptal needles and sheaths, steerable sheaths; interventional cardiology and peripheral intervention products such as introducer kits, guiding extension catheters, balloon catheters, guiding catheters, microcatheters, guidewires, hydrophilic angiographic catheters, hydrophilic guidewires, hemostasis introducers, radial compression devices, aspiration catheters, inflation devices, Y connectors, snare kits, hemostasis valves, L guiding sheaths, balloon occlusion microcatheters, embolic protection devices, transjugular liver access sets and steerable guiding sheaths; and neurointervention devices, alongside OEM/ODM services encompassing project design, development, customization and volume production. Founded in 2002 and headquartered in Shenzhen, China, APT Medical operates primarily in the healthcare sector with approximately 2,155 employees and serves clinicians, hospitals and academic institutions across electrophysiology, cardiology, peripheral and neurointervention segments in over 30 countries. In 2024, Mindray Bio-Medical Electronics announced a $927 million deal to acquire a 21.12% controlling stake in APT Medical from existing shareholders, aiming to leverage Mindray's global sales network for expanded international reach and integrate equipment with APT's consumables for cardiovascular treatments. Recently in 2025, APT Medical achieved milestones including the first pulsed-field ablation procedures with its 3D mapping platform in Indonesia and showcased innovations like AForcePlus PFA catheters and HT Viewer 3D Mapping System at events such as EuroPCR 2025 and expert exchanges at Beijing Anzhen and Fuwai Hospitals, highlighting expansions in complex PCI and arrhythmia treatments.